Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Carcinoma, Hepatocellular 26Small Cell Lung Carcinoma 17Lung Neoplasms 15Neoplasms 13Breast Neoplasms 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Melanoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Carcinoma, Transitional Cell 5Prostatic Neoplasms 4Glioblastoma 4Stomach Neoplasms 3Solid Tumors 3Sarcoma, Alveolar Soft Part 3Sarcoma 3Liver Neoplasms 3Extensive Stage Lung Small Cell Carcinoma 3Carcinoma 3Treatment-Refractory Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Nasopharyngeal Carcinoma 2

Interventions

Cisplatin 18Gemcitabine 14Radiotherapy, Intensity-Modulated 11Magnetic Resonance Spectroscopy 8toripalimab 7Specimen Handling 7Capecitabine 7Platinum 5Drug Therapy 51,2-diaminocyclohexaneplatinum II citrate 5camrelizumab 4Radiotherapy 4Nivolumab 4spartalizumab 3sintilimab 3anlotinib 3Immunoglobulin G 3Immune Checkpoint Inhibitors 3Docetaxel 3Disulfides 3atezolizumab 2Radiation 2Phantoms, Imaging 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 218-O-demethylcervinomycin A2 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × atezolizumab × 90 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡